TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04993898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training with warm up and cool down
Description: These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training with warm up & cool down
Description: These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
Study: NCT05583253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Small gauge pars-plana vitrectomy for management of retinal detachment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Small gauge pars-plana vitrectomy for management of retinal detachment.
Study: NCT01566916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Study: NCT04861233

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05184361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Description: Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous energy restriction (CER)
Description: A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
Study: NCT05107024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFR-guided step by step balloon dilation
Description: The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional balloon dilation
Description: The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
Study: NCT04961749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
Study: NCT06124066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG
Description: The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron 50 MG
Description: The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG
Description: The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
Study: NCT04618757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hedonic Reward
Description: A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Reward
Description: A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
Study: NCT05056896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule taken orally
Study: NCT05678023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect on contrast media depending on the time of its administratsion
Description: CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect on contrast media depending on the time of its administratsion
Description: CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
Study: NCT05756335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Un)predictable and (un)attended stimuli
Description: Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
Study: NCT05849311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab with new manufacturing process
Description: Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab with old manufacturing process
Description: Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously.
Study: NCT04848233

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Drinks containing 5AA+CrPic and Placebo
Description: Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
Study: NCT06377345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeviceMD device
Description: The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
Study: NCT05782179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to alhydrogel as an adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to alhydrogel as an adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to alhydrogel as an adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to alhydrogel as an adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9 %

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9 %

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9 %

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9 %
Study: NCT04699071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab and lenvatinib
Description: All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent.
Study: NCT05596903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR 2.0 group protocol
Description: EMDR 2.0 group protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mhgap stress module
Description: Mhgap stress module
Study: NCT06308640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of the device intraorally
Description: * The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of the device intraorally
Description: * The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance
Study: NCT06489938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impairment-oriented approach
Description: The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impairment-oriented approach
Description: The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
Study: NCT06243068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educate and Engage
Description: Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.
Study: NCT04730362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: guedel airway
Description: Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway
Description: supraglottic airway

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol bolus and then anesthesia sevoflurane
Description: Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol bolus and then anesthesia sevoflurane
Description: Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
Study: NCT05310994

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wasabi Leaf Extract Drink
Description: consume 1 bottle per day
Study: NCT05298644

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide

Intervention type: DRUG
Group type: OTHER
Intervention: Active Comparator
Description: Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.

Intervention type: DRUG
Group type: OTHER
Intervention: Active Comparator
Description: Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
Study: NCT05646446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Program
Description: The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
Study: NCT05160714

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Real-time ADC-guided response adaptive Boost in HNC
Description: 40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy
Study: NCT05319457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The radon app
Description: Participants will be asked to use the radon app.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Print brochure
Description: Participants will receive print brochures.
Study: NCT04939025

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multi-interventional program
Description: 1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease.
Study: NCT05005988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actions for Empowered Maternal Neonatal Care
Description: The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting.
Study: NCT06243068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educate and Engage Plus Kidney Supportive Care Program
Description: In addition to bundle described under Educate and Engage, nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist.
Study: NCT06007677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous injection.
Study: NCT06392906

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation therapy
Description: 5 daily radiation treatments
Study: NCT05965388

Intervention type: DRUG
Intervention: nucleoside analogues or interferon
Description: ETV、TDF、TAF、TAF、IFN-a-2b
Study: NCT06392906

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard course radiation therapy
Description: 10 daily radiation treatments
Study: NCT06520397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab and Upadacitinib
Description: Participants in this group will maintain the original Ustekinumab regimen, receiving 90 mg administered subcutaneously every 8 weeks. In addition, they will receive Upadacitinib administered orally at a dosage of 45 mg daily for 12 weeks. After the 12-week period, the dosage of Upadacitinib will be adjusted based on patient condition and clinical judgment, continuing until the evaluation at week 16. Clinical efficacy of the dual-target therapy will be evaluated at week 16.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Participants will receive an additional induction dose of Ustekinumab administered intravenously at 6 mg/kg at baseline. This will be followed by subcutaneous maintenance therapy of 90 mg every 4 weeks. Clinical efficacy will be evaluated at week 16.
Study: NCT05906771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolaid(R)
Description: The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~The nutraceutical has been elaborated by Monteloeder, S.L. It is a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves. The dose that the participants of the experimental group will receive will be 300mg plus 20mg of microcrystalline cellulose. The product is presented in an unflavored capsule, it is a reddish-brown powder with a characteristic odor and a slightly bitter taste. The manufacturing date of the product was 01/12/2022 and the expiration date was 30/11/2024.
Study: NCT04761146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DaRT Diffusing Alpha-emitters Radiation Therapy
Description: DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.